ACADIA PHARMACEUTICALS INC (ACAD) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does ACADIA PHARMACEUTICALS INC Do?
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. ACADIA PHARMACEUTICALS INC (ACAD) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Stephen R. Davis and employs approximately 510 people, headquartered in SAN DIEGO, California. With a market capitalization of $3.8B, ACAD is one of the notable companies in the Healthcare sector.
ACADIA PHARMACEUTICALS INC (ACAD) Stock Rating — Reduce (April 2026)
As of April 2026, ACADIA PHARMACEUTICALS INC receives a Reduce rating with a composite score of 43.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ACAD ranks #2,713 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ACADIA PHARMACEUTICALS INC ranks #367 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ACAD Stock Price and 52-Week Range
ACADIA PHARMACEUTICALS INC (ACAD) currently trades at $21.74. The stock lost $0.83 (3.7%) in the most recent trading session. The 52-week high for ACAD is $28.35, which means the stock is currently trading -23.3% from its annual peak. The 52-week low is $13.40, putting the stock 62.2% above its annual trough. Recent trading volume was 849K shares, suggesting relatively thin trading activity.
Is ACAD Overvalued or Undervalued? — Valuation Analysis
ACADIA PHARMACEUTICALS INC (ACAD) carries a value factor score of 55/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 25.08x, compared to the Healthcare sector average of 23.63x — a premium of 6%. The price-to-book ratio stands at 3.07x, versus the sector average of 2.75x. The price-to-sales ratio is 3.63x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ACAD trades at 31.63x EV/EBITDA, versus 6.34x for the sector.
Overall, ACAD's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
ACADIA PHARMACEUTICALS INC Profitability — ROE, Margins, and Quality Score
ACADIA PHARMACEUTICALS INC (ACAD) earns a quality factor score of 43/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 12.2%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 9.6% versus the sector average of -33.1%.
On a margin basis, ACADIA PHARMACEUTICALS INC reports gross margins of 92.1%, compared to 71.5% for the sector. The operating margin is 11.4% (sector: -66.1%). Net profit margin stands at 14.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 15.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
ACAD Debt, Balance Sheet, and Financial Health
ACADIA PHARMACEUTICALS INC has a debt-to-equity ratio of 27.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.83x, indicating strong short-term liquidity. Total debt on the balance sheet is $43M. Cash and equivalents stand at $258M.
ACAD has a beta of 0.86, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for ACADIA PHARMACEUTICALS INC is 57/100, reflecting average volatility within the normal range for its sector.
ACADIA PHARMACEUTICALS INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, ACADIA PHARMACEUTICALS INC reported revenue of $1.04B and earnings per share (EPS) of $2.32. Net income for the quarter was $150M. Gross margin was 92.1%. Operating income came in at $119M.
In FY 2025, ACADIA PHARMACEUTICALS INC reported revenue of $1.07B and earnings per share (EPS) of $2.32. Net income for the quarter was $391M. Gross margin was 91.7%. Revenue grew 11.9% year-over-year compared to FY 2024. Operating income came in at $105M.
In Q3 2025, ACADIA PHARMACEUTICALS INC reported revenue of $279M and earnings per share (EPS) of $0.43. Net income for the quarter was $72M. Gross margin was 92.2%. Revenue grew 11.3% year-over-year compared to Q3 2024. Operating income came in at $36M.
In Q2 2025, ACADIA PHARMACEUTICALS INC reported revenue of $265M and earnings per share (EPS) of $0.16. Net income for the quarter was $27M. Gross margin was 92.2%. Revenue grew 9.3% year-over-year compared to Q2 2024. Operating income came in at $32M.
Over the past 8 quarters, ACADIA PHARMACEUTICALS INC has demonstrated a growth trajectory, with revenue expanding from $242M to $1.04B. Investors analyzing ACAD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ACAD Dividend Yield and Income Analysis
ACADIA PHARMACEUTICALS INC (ACAD) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ACAD Momentum and Technical Analysis Profile
ACADIA PHARMACEUTICALS INC (ACAD) has a momentum factor score of 49/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 27/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 11/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
ACAD vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, ACADIA PHARMACEUTICALS INC (ACAD) ranks #367 out of 838 stocks based on the Blank Capital composite score. This places ACAD in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing ACAD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ACAD vs S&P 500 (SPY) comparison to assess how ACADIA PHARMACEUTICALS INC stacks up against the broader market across all factor dimensions.
ACAD Next Earnings Date
No upcoming earnings date has been announced for ACADIA PHARMACEUTICALS INC (ACAD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ACAD? — Investment Thesis Summary
The quantitative profile for ACADIA PHARMACEUTICALS INC suggests caution.
In summary, ACADIA PHARMACEUTICALS INC (ACAD) earns a Reduce rating with a composite score of 43.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ACAD stock.
Related Resources for ACAD Investors
Explore more research and tools: ACAD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ACAD head-to-head with peers: ACAD vs AZN, ACAD vs SLGL, ACAD vs VMD.